178619-81-3Relevant academic research and scientific papers
Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives
Fray,Bull,Carr,Gautier,Mowbray,Stobie
, p. 1951 - 1962 (2001)
A series of 6,7-dichloro-1,4-dihydro-(1H, 4H)-quinoxaline-2,3-diones (1-17) were prepared in which the 5-position substituent was a heterocyclylmethyl or 1-(heterocyclyl)-1-propyl group. Structure-activity relationships were evaluated where binding affini
QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS
-
, (2008/06/13)
Compounds of formula (I): STR1 and their pharmaceutically acceptable salts, wherein R 1 and R 2 are each independently Cl, Br, CH 3, CH 2 CH 3 or CF 3 ; R 3 is H, CH 3 or CH 2 CH 3 ; and X is a 5-membered heterocyclic group containing up to four nitrogen atoms, attached via a nitrogen atom, the said group being optionally substituted by C 1-C 6 alkyl or (CH 2) n NR 4 R 5, wherein n is an integer from 1 to 5 and R 4 and R. sup.5 are each independently H, C. sub.1-C 6 alkyl, C 3-C 6 cycloalkyl or C 1-C 4 alkyl substituted by phenyl or pyridyl, or R 4 and R 5 are linked to form, together with the nitrogen atom to which attached, a pyrrolidine, piperidine, piperazine, N-(C 1-C. sub.4 alkyl) piperazine, morpholine or azepine group, or, when X is triazolyl, said group may optionally be benzofused, are NMDA antagonists of value in the treatment of acute neurodegenerative disorders, e.g. arising from stroke or traumatic head injury and in chronic neurological disorders, e.g. senile dementia and Alzheimer's disease.
Quinoxaline derivatives useful in therapy
-
, (2008/06/13)
Compounds of formula (I), wherein A represents N or CH; R1 and R2 independently represent C1-4 alkyl, halo or CF3 ; R3 represents C1-4 alkyl (optionally substituted), C3-7 cycloa
